Pharmacology/Pharmaceutical Industry | Page 58 of 172 | Links Medicus Content Curation & Alerts in Medicine

[Preprint] RCT: Fluvoxamine reduced the risk for ER visits and hospitalization among patients with Covid-19.

24 Aug, 2021 | 10:06h | UTC

RCT: Effect of Early Treatment with Fluvoxamine on Risk of Emergency Care and Hospitalization Among Patients with COVID-19 – Together Clinical Trials

Opinion | Could this be our first effective, inexpensive, widely available outpatient treatment for COVID-19? (It’s fluvoxamine).

Preliminary study shows fluvoxamine may reduce clinical deterioration in outpatients with symptomatic COVID-19

Commentary on Twitter

@TogetherTrial Manuscript Pre-print regarding #Fluvoxamine for early #COVID19 is online athttps://t.co/teHqMlowld
demonstrating ~30% relative reduction in ER visits / hospitalizations with fluvoxamine 100mg 2x/day in a 10-site, double-blind randomized trial. #IDtwitter pic.twitter.com/727by0lqft

— David Boulware, MD MPH (@boulware_dr) August 23, 2021

Opinion | The FDA really did have to take this long – “If vaccine approval feels maddeningly scrupulous, that’s because the alternative is worse”.

24 Aug, 2021 | 10:01h | UTC

The FDA Really Did Have to Take This Long – The Atlantic

COVID vaccines protect against Delta, but their effectiveness wanes.

24 Aug, 2021 | 09:57h | UTC

COVID vaccines protect against Delta, but their effectiveness wanes – Nature

Original study: [Preprint] Pfizer vaccine effectiveness against Delta declines faster than AstraZeneca, both offering the same protection after 4 months.

Guideline for immunizations in patients with inflammatory bowel disease.

24 Aug, 2021 | 09:00h | UTC

Canadian Association of Gastroenterology Clinical Practice Guideline for Immunizations in Patients With Inflammatory Bowel Disease (IBD)—Part 1: Live Vaccines – Gastroenterology

Canadian Association of Gastroenterology Clinical Practice Guideline for Immunizations in Patients With Inflammatory Bowel Disease (IBD)—Part 2: Inactivated Vaccine – Gastroenterology

RCT: SGLT2 inhibition reduces the risk of hyperkalemia in patients with diabetes and chronic kidney disease.

24 Aug, 2021 | 08:57h | UTC

Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial – European Heart Journal (link to abstract – $ for full-text)

Commentary on Twitter

SGLT2 inhibition reduces the risk of serious hyperkalemia in people with diabetic kidney disease, which may enable greater use of RAAS inhibitors in CKD and/or heart failure

New CREDENCE data presented this week at #ESCCongress, now in @ESC_Journals:https://t.co/OEqnXTdBDi pic.twitter.com/zsanEFZVCy

— Brendon Neuen (@brendonneuen) August 23, 2021

Systematic review: Pain management after complex spine surgery.

24 Aug, 2021 | 08:50h | UTC

Pain management after complex spine surgery – European Journal of Anaesthesiology

Among patients receiving mRNA vaccines, clinically significant symptoms were more frequent following dose 2, following dose 1 in patients with previous SARS-CoV-2 infection, and in those who received the Moderna vaccine.

22 Aug, 2021 | 23:54h | UTC

Association of Vaccine Type and Prior SARS-CoV-2 Infection With Symptoms and Antibody Measurements Following Vaccination Among Health Care Workers – JAMA Internal Medicine

Commentary on Twitter

New @JAMA_current paper says @moderna_Tx caused 2.3x the number of "significant" symptoms compared to @pfizer in a sample of 950 people.

Moderna also produced more antibodies. Raising the question of what a third dose, which produces still MORE, will do.https://t.co/drvhhsnpHo

— Alex Berenson (@AlexBerenson) August 16, 2021

[Preprint] Study shows symptomatic breakthrough infections are probably less transmissible than SARS-CoV-2 infections in unvaccinated individuals.

22 Aug, 2021 | 23:59h | UTC

Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine-breakthrough infections: a multi-center cohort study – medRxiv

Commentary on Twitter (thread – click for more)

Did you hear vaccinated people with Delta “have just as much virus in their nose so are just as infectious as unvaccinated”?

Turns out vaccinated people have significantly less culturable virus present at the same Ct count

They are LESS INFECTIOUS 💥 https://t.co/OX0Ul0ntWc pic.twitter.com/3vDQSJ6j84

— Alasdair Munro (@apsmunro) August 22, 2021

Lab study shows a heterologous AstraZeneca + Pfizer immunization strategy provides stronger immunogenicity against Covid compared to homologous AZ + AZ or Pfizer + Pfizer strategies.

22 Aug, 2021 | 23:51h | UTC

Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study – The Lancet Respiratory Medicine

Invited Commentary: Heterologous ChAdOx1-nCoV19–BNT162b2 vaccination provides superior immunogenicity against COVID-19

Lab study shows heterologous AstraZeneca/Pfizer vaccination produces strong immune response against SARS-CoV-2 Delta variant.

RCT: Safety and immunogenicity of heterologous vs. homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine.

Another study shows increased immune response with heterologous Oxford-AstraZeneca/mRNA vaccination (several articles on the subject)

Commentary on Twitter

NEW Research—Heterologous ChAdOx1 nCov-19–BNT162b2 immunisation w/ 10–12-week interval is well tolerated & improves immunogenicity vs homologous ChAdOx1 nCov-19 vax w/ 10–12-week interval & BNT162b2 vax w/ 3-week interval

Study from Prof Sander & co https://t.co/VAB54NokSi pic.twitter.com/wfeBsvoKhO

— The Lancet Respiratory Medicine (@LancetRespirMed) August 13, 2021

CoronaVac vaccine in older adults during a gamma variant associated epidemic of covid-19 in Brazil – Effectiveness against symptomatic disease was 46.8%, 55.5% against hospitalization, and 61.2% against deaths.

22 Aug, 2021 | 23:48h | UTC

Effectiveness of the CoronaVac vaccine in older adults during a gamma variant associated epidemic of covid-19 in Brazil: test negative case-control study – The BMJ

Editorial: Real world effectiveness of covid-19 vaccines

Related: CoronaVac vaccine: its results are patchy, but the world can’t ignore its usefulness. (several texts on the subject)

Observational data from Canada: Effectiveness of mRNA covid-19 vaccines was 91% against symptomatic disease and 98% against hospitalization and deaths.

22 Aug, 2021 | 23:47h | UTC

Effectiveness of BNT162b2 and mRNA-1273 covid-19 vaccines against symptomatic SARS-CoV-2 infection and severe covid-19 outcomes in Ontario, Canada: test negative design study – The BMJ

Editorial: Real world effectiveness of covid-19 vaccines

M-A: GLP-1 receptor agonists reduce major adverse cardiovascular events, all-cause mortality, hospital admission for heart failure, and worsening kidney function in patients with type 2 diabetes.

22 Aug, 2021 | 22:50h | UTC

Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials – The Lancet Diabetes & Endocrinology (link to abstract – $ for full-text)

M-A: The role of SGLT2 inhibitors in heart failure.

22 Aug, 2021 | 22:46h | UTC

The Role of SGLT2 Inhibitors in Heart Failure: A Systematic Review and Meta-Analysis – Cardiology Research and Practice

E SC Position Paper: Cardiac, renal, and metabolic effects of SGLT2 inhibitors.

Guideline: SGLT-2 inhibitors or GLP-1 receptor agonists for adults with type 2 diabetes – This guidance recommends a risk-based approach, advising against starting SGLT-2 inhibitors or GLP-1 receptor agonists in patients with three or fewer cardiovascular risk factors and without established CVD or CKD.

Summary: SGLT2 inhibitors and GLP-1 receptor agonists established and emerging indications.

M-A: SGLT2 inhibitors decrease cardiovascular death and heart failure hospitalizations in patients with heart failure.

Meta-analysis: Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with Type 2 diabetes

#ESCCongress – [Abstract Only] SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: A meta-analysis of the EMPEROR-Reduced and DAPA-HF trials

[Abstract Only] Randomized Trial: SGLT2 Inhibitor Improves Outcomes in Patients with Heart Failure Even in the Absence of Diabetes

Study: Macrolide use significantly associated with both prevalent and incident tinnitus.

22 Aug, 2021 | 22:11h | UTC

Macrolide-associated ototoxicity: a cross-sectional and longitudinal study to assess the association of macrolide use with tinnitus and hearing loss – Journal of Antimicrobial Chemotherapy

Commentary: Macrolide Use and Tinnitus: A New Safety Ringtone? – NEJM Journal Watch (free for a limited period)

[Preprint] Pfizer vaccine effectiveness against Delta declines faster than AstraZeneca, both offering the same protection after 4 months.

20 Aug, 2021 | 10:03h | UTC

Impact of Delta on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK – University of Oxford

Commentaries:

Vaccines Are Less Effective Against Delta—And Pfizer’s Protection Wanes Rapidly—But Are The Best Way To Protect Against Covid, Large Study Finds – Forbes

Expert reaction to preprint looking at the impact of the delta variant on vaccine effectiveness – Science Media Centre

Pfizer vaccine effectiveness declines faster than AstraZeneca – study – Evening Standard

Commentary on Twitter

New large UK study confirms attrition of @Pfizer vaccine effectiveness vs Delta infections over time https://t.co/K6YRyAQq4o "By roughly 4 1/2 months after the 2nd dose, Pfizer’s shot will probably be about on par with Astra’s at preventing infections with a high viral burden" pic.twitter.com/x1Nl2BkWfn

— Eric Topol (@EricTopol) August 19, 2021

Treatment escalation vs. immediate initiation of highly effective treatment for patients with relapsing-remitting multiple sclerosis: data from 2 different national strategies.

22 Aug, 2021 | 22:06h | UTC

Treatment Escalation vs Immediate Initiation of Highly Effective Treatment for Patients With Relapsing-Remitting Multiple Sclerosis: Data From 2 Different National Strategies – JAMA Neurology (free for a limited period)

Commentary on Twitter

Study suggests that escalation of #multiplesclerosis treatment was inferior to initial treatment with a more effective disease-modifying agent https://t.co/hkHsAXP5se

— JAMA Neurology (@JAMANeuro) August 16, 2021

Prescription medications for use in pregnancy – perspective from the US Food and Drug Administration.

20 Aug, 2021 | 08:55h | UTC

Prescription medications for use in pregnancy–perspective from the US Food and Drug Administration – American Journal of Obstetrics & Gynecology

Commentary on Twitter

"There are only 9 [NINE!] drugs that have ever been approved and marketed in the United States for obstetrical indications."

Pregnant individuals deserve data to help them make informed decisions. #ResearchPregnancy https://t.co/sj7dWUzKNZ

— All Source Pregnancy (@PregnancyAll) July 17, 2021

Study finds increased risk of gastrointestinal bleeding following concomitant treatment with oral glucocorticoids in patients on non-vitamin K oral anticoagulants.

20 Aug, 2021 | 08:45h | UTC

Gastrointestinal bleeding risk following concomitant treatment with oral glucocorticoids in patients on non-vitamin K oral anticoagulants – Heart (link to abstract – $ for full-text)

Commentary on Twitter

In this @Heart_BMJ #Afib sdy @AndersHolt6 et al. found a X2 ⬆️ risk of GI bleeding w/ NOAC💊+oral glucocorticoids⚪ vs NOAC alone 💊

Authors recommend ☝️ close monitoring 👀 or other risk 🛑 mitigation when co-prescribing

📝 https://t.co/CgtgmvnD29 #CardioTwitter #cardiology pic.twitter.com/95eCOWxozK

— Copenhagen Cardiovascular Research Center (@CopCard) August 15, 2021

Extended-spectrum β-lactamases: an update on their characteristics, epidemiology and detection.

20 Aug, 2021 | 08:41h | UTC

Extended-spectrum β-lactamases: an update on their characteristics, epidemiology and detection – JAC-Antimicrobial Resistance

IDSA response to plan for supplemental vaccine doses for vaccinated individuals.

19 Aug, 2021 | 09:02h | UTC

Response to Plan for Supplemental Vaccine Doses for Vaccinated Individuals – Infectious Diseases Society of America

Studies: COVID vaccine protection waning against infection but not hospitalization.

19 Aug, 2021 | 09:05h | UTC

Studies: COVID vaccine protection waning against infection but not hospitalization – CIDRAP

Study 1: Sustained Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Associated Hospitalizations Among Adults — United States, March–July 2021 – CDC Morbidity and Mortality Weekly Report

Study 2: Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant — National Healthcare Safety Network, March 1–August 1, 2021 – CDC Morbidity and Mortality Weekly Report

Study 3: New COVID-19 Cases and Hospitalizations Among Adults, by Vaccination Status — New York, May 3–July 25, 2021 – CDC Morbidity and Mortality Weekly Report

Commentary on Twitter (thread – click for more)

Very excited to share our most recent publication about #CovidVaccine effectiveness, just published today by the IVY network. Especially relevant in light of today’s news about #boosters (spoiler – I’m skeptical about the need for boosters for all). 🧵https://t.co/GbAxgzpo7R

— Nida Qadir, MD (@NidaQadirMD) August 18, 2021

U.S. officials’ decision on Covid-19 booster shots baffles — and upsets — some scientists.

19 Aug, 2021 | 09:00h | UTC

U.S. officials’ decision on Covid-19 booster shots baffles — and upsets — some scientists – STAT

Commentary on Twitter

Scientists I spoke to today had a lot of questions about the administration's decision to start giving Americans 3rd doses of the mRNA vaccines next month. “I’m not sure we had enough [data] to pull the trigger right now," one said. https://t.co/eHUndOrQL4

— Helen Branswell 🇨🇦 (@HelenBranswell) August 18, 2021